Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101088 | 0.99 | MTNR1B (0.54) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3096267 | 0.99 | MTNR1B (0.54) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3099687 | 0.97 | MTNR1B (0.55) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3099691 | 0.89 | MTNR1B (0.53) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3103891 | 0.88 | ALDH1A1 (0.53) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3101003 | 0.88 | MTNR1B (0.52) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3096747 | 0.84 | MTNR1B (0.48) | MTNR1BTSHRCNR1MEN1KMT2A | |
| SCHEMBL3096278 | 0.83 | MTNR1B (0.47) | MTNR1BTSHRCNR1HPGDHTR3E | |
| SCHEMBL3086983 | 0.82 | CNR1 (0.50) | MTNR1BTSHRCNR1HPGDHTR3E | |
| SCHEMBL3104061 | 0.80 | TSHR (0.77) | TSHRMEN1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | claimed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | claimed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | claimed |
| US-8604190-B2 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-10 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | GAUL MICHEAL D | 2010-10-07 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| US-7622579-B2 | (1-o-Tolyl-piperidin-4-yl)-thiomorpholin-4-yl-methanone; useful for treating diseases and conditions selected from osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, sunburn, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-24 | — | — | US | disclosed |
| EP-1768959-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006004793-A2 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288281-A1 | Hetero isonipecotic modulators of vanilloid VR1 receptor | VDAC1, HVCN1, TRPV1 | MTNR1B 244/4885TSHR 3231/4885CNR1 13/4885 |
| US-20100256359-A1 | HETERO ISONIPECOTIC MODULATORS OF VANILLOID VR1 RECEPTOR | VDAC1, HVCN1, TRPV1 | MTNR1B 244/4885TSHR 3231/4885CNR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.